CooperVision announced today that it has received U.S. Food and Drug Administration (FDA) approval of its innovative MiSight® 1 day contact lens1. The cornerstone of a comprehensive myopia management approach to be offered by CooperVision, this daily wear, single use contact lens is the first and only FDA-approved product1 clinically proven to slow the progression of myopia (nearsightedness or short-sightedness) when initially prescribed for children 8-12 years old*.
Stay tuned to the Myopia Managment Center page for updates.
1 MiSight® (omafilcon A) daily wear single use Soft Contact Lenses are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
* when compared to the children in the control group wearing a single vision 1-day contact lens.